CN101433556A - Health product composition containing placenta component and preparation method - Google Patents
Health product composition containing placenta component and preparation method Download PDFInfo
- Publication number
- CN101433556A CN101433556A CNA2008101477737A CN200810147773A CN101433556A CN 101433556 A CN101433556 A CN 101433556A CN A2008101477737 A CNA2008101477737 A CN A2008101477737A CN 200810147773 A CN200810147773 A CN 200810147773A CN 101433556 A CN101433556 A CN 101433556A
- Authority
- CN
- China
- Prior art keywords
- placenta
- people
- powder
- vitamin
- halth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000002826 placenta Anatomy 0.000 title claims abstract description 70
- 239000000203 mixture Substances 0.000 title claims abstract description 29
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 230000036541 health Effects 0.000 title description 8
- 239000000843 powder Substances 0.000 claims abstract description 36
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 22
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 22
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 11
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 11
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 11
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 11
- 239000011718 vitamin C Substances 0.000 claims abstract description 11
- 229940046009 vitamin E Drugs 0.000 claims abstract description 11
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 11
- 239000011709 vitamin E Substances 0.000 claims abstract description 11
- 238000002156 mixing Methods 0.000 claims description 17
- 239000007901 soft capsule Substances 0.000 claims description 15
- 235000012424 soybean oil Nutrition 0.000 claims description 13
- 239000003549 soybean oil Substances 0.000 claims description 13
- 239000004615 ingredient Substances 0.000 claims description 10
- 239000003921 oil Substances 0.000 claims description 10
- 235000019198 oils Nutrition 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 7
- 235000004347 Perilla Nutrition 0.000 claims description 5
- 244000124853 Perilla frutescens Species 0.000 claims description 5
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 5
- 235000019486 Sunflower oil Nutrition 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims description 5
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims description 5
- 210000000582 semen Anatomy 0.000 claims description 5
- 239000002600 sunflower oil Substances 0.000 claims description 5
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 5
- 239000008158 vegetable oil Substances 0.000 claims description 5
- 239000000470 constituent Substances 0.000 claims description 4
- 238000007710 freezing Methods 0.000 claims description 4
- 230000008014 freezing Effects 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 2
- 238000000859 sublimation Methods 0.000 claims description 2
- 230000008022 sublimation Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 13
- 239000003814 drug Substances 0.000 abstract description 11
- 238000012360 testing method Methods 0.000 abstract description 8
- 208000003351 Melanosis Diseases 0.000 abstract description 4
- 208000037259 Amyloid Plaque Diseases 0.000 abstract description 3
- 206010008570 Chloasma Diseases 0.000 abstract description 3
- 240000008397 Ganoderma lucidum Species 0.000 abstract description 3
- 235000001637 Ganoderma lucidum Nutrition 0.000 abstract description 3
- 150000004676 glycans Chemical class 0.000 abstract description 3
- 229920001282 polysaccharide Polymers 0.000 abstract description 3
- 239000005017 polysaccharide Substances 0.000 abstract description 3
- 108090000623 proteins and genes Proteins 0.000 abstract description 3
- 102000004169 proteins and genes Human genes 0.000 abstract description 3
- 238000005562 fading Methods 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 21
- 239000008187 granular material Substances 0.000 description 11
- 238000001035 drying Methods 0.000 description 10
- 238000005303 weighing Methods 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 108010010803 Gelatin Proteins 0.000 description 7
- -1 drying Substances 0.000 description 7
- 229920000159 gelatin Polymers 0.000 description 7
- 239000008273 gelatin Substances 0.000 description 7
- 235000019322 gelatine Nutrition 0.000 description 7
- 235000011852 gelatine desserts Nutrition 0.000 description 7
- 239000005556 hormone Substances 0.000 description 7
- 229940088597 hormone Drugs 0.000 description 7
- 238000012856 packing Methods 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 230000036039 immunity Effects 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 241000283898 Ovis Species 0.000 description 4
- 230000000975 bioactive effect Effects 0.000 description 4
- 239000007902 hard capsule Substances 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 229920001353 Dextrin Polymers 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102000009151 Luteinizing Hormone Human genes 0.000 description 2
- 108010073521 Luteinizing Hormone Proteins 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 241000222336 Ganoderma Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 210000001691 amnion Anatomy 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960004407 chorionic gonadotrophin Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 210000002816 gill Anatomy 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to a health-care product composition containing a placenta component and a preparation method thereof. The composition uses ganoderma lucidum polysaccharide and human placenta powder as basic effective components which can be formed together with at least one of vitamin E and vitamin C when necessary and pharmaceutically acceptable assistant components, wherein the weight ratio of the ganoderma lucidum polysaccharide to the human placenta powder expressed by amount of protein in the effective components is between 1 to 0.1 and 1 to 5, preferably between 1 to 0.1 and 1 to 1. Through tests, the composition not only can enhance immunological competence of human body, but also can delay senility, has remarkable fading effect on senile plaque or chloasma, and is remarkably superior to the prior homogeneous medicament and/or health-care products containing the placenta component on effect.
Description
Technical field
The present invention relates to a kind of Halth-care composition that strengthens human body immunity and function of delaying senility that has, specifically is a kind of Halth-care composition that contains placenta component, and the preparation method of these health product.
Background technology
Having in the natural materials that strengthens human body immunity and function of delaying senility of existing research at present, Ganoderma, particularly its effective ingredient ganoderan, has the multiple bioactive ingredients that human body is had health-care effect, as can activated immune system and inducing interferon function, the intravital tumor cell of people is constrained, the hormone of cell also can produce indirect action, thereby the growth of blocking-up tumor cell makes death of neoplastic cells reach anticancer purpose; Can improve the side effect that medicine becomes radiation cure to cause, significant to treatment and prevention of tumour; High/low blood pressure there is dual regulation; Improve hyperlipemia, hypoglycemic activity; Antianaphylaxis or the like.At present existing Ganoderma lucidum polysaccharides health-care product use in reality, thereby its main effect is to improve immunity to strengthen body constitution.
On the other hand, mammiferous Placenta Hominis, people's Placenta Hominis particularly, because of containing naturally occurring endogenous bioactive substances such as many important aminoacid, hormone, somatomedin with physiological function and biologic activity, very early as a kind of important source material that can have the medicine and/or the health product of multiple physiologically active and beneficial functional, as, with animal Placenta Hominiss such as Placenta caprae seu oviss is the multiple medicine of raw material or the goods of health product, and contains Placenta Hominis capsule, people's Placenta Hominis Tabellae, Plancenta Histolysate of people's placenta component etc.Because endogenous bioactive substance goods can be avoided the untoward reaction, particularly people's Placenta Hominis of many other types medicines in application, a kind of especially important and good humanized's medicament sources is much accounted of day by day and extensive studies and application is arranged.For example, people's placental article is used to treat climacteric syndrome and multiple chronic disease in extensive use in department of dermatologry, gynecological, surgery on the clinical medicine at present.Chinese medicine thinks that more already it can have effects such as strengthening by means of tonics, nourishing blood and replenishing essence, happiness kidney and enhancing body, replenishing QI to invigorate the spleen, can be used for the treatment of aspects such as malnutrition, inappetence, neurasthenia, insufficiency of blood body void, refreshing empty sexual impotence, freckle, black all endocrine disturbance of reaching of the dark skin of face.
Research is also found, because the animal Placenta Hominis is compared with people's Placenta Hominis, aspect a lot of, still there are a lot of differences, particularly very big-difference is arranged at aspects such as main components such as aminoacid, hormone, somatomedin and ratios, thereby its nutritive value and curative effect have been influenced, and because of it contains non-humanized's foreign protein, rejection etc. takes place easily.The health food that for example contains the animal placenta component at present mainly also just is used to suppress aspects such as senile plaque or chloasma.People's Placenta Hominis then is a kind of good humanized's medicine, meets adjusting and treatment to human biology most.But because when people's Placenta Hominis raw material is handled, traditional drying mode is adopt to steam, boil or means such as baking, thereby the destruction that can cause being subjected to as enzyme, hormone etc. thermally labile component, influenced the performance of its effect, also wasted the not abundant valuable source in source.
Summary of the invention
In view of the foregoing, the present invention will provide a kind of Halth-care composition that contains placenta component, to give full play to the effect that it strengthens human body immunity and slow down aging.The present invention further also will provide a kind of preparation method of these health product.
The present invention contains the Halth-care composition of placenta component, be to be basic effective constituents with ganoderan and people's Placenta Hominis powder, form jointly with acceptable auxiliary element in the pharmacy, the weight ratio of people's Placenta Hominis powder that ganoderan is represented with albumen quality in the effective ingredient is 1/ (0.1～5), and preferred proportion is 1/ (0.1～1).
In above-mentioned composition, said people's Placenta Hominis powder is the ultra-micro powder of 1 μ m～50 μ m to adopt particle diameter, and particularly the people's Placenta Hominis drying ultra-micro powder that obtains in the freezing and sublimation mode under-40 ℃～-45 ℃ and 15Pa～25Pa condition is good.
Different according to application target and application in the composition of above-mentioned composition, further can also be added at least a in vitamin E, the vitamin C in the said effective ingredient.The amount of adding can determine that for example vitamin E can be by 20～100mg/ days usage ratio according to the safe level scope of health food regulation, and vitamin C can add by 50～300mg/ days usage ratio.
The Halth-care composition that the present invention is above-mentioned can be made the product of multiple different concrete forms, as different dosage form forms such as soft capsule, hard capsule, tablets.Test shows, be good wherein to adopt the soft capsule preparation form that is prepared into by said effective ingredient and auxiliary element, because the preparation of soft capsule itself is a closed system, can cover bad smell, guarantee that dosage is accurate, oxygen in simultaneously can secluding air, help keeping protein, hormone and vitamin etc. stable in ganoderan and the placenta component, guaranteed curative effect, improved safety.When wherein preparing soft capsule in the optional PEG400 of used auxiliary element, the polyethylene glycol 6000 one or both, or vegetable oil, wherein optional in soybean oil, Semen Maydis oil, sunflower oil, Oleum Bulbus Allii, perilla oil one or more of vegetable oil.
The above-mentioned preparation that contains the Halth-care composition of placenta component of the present invention, can adopt following manner to carry out: with people's Placenta Hominis after fully freezing under-40 ℃～-45 ℃ conditions, after 15Pa～25Pa lyophilization, being crushed to particle diameter is the ultra-micro powder of 1 μ m～50 μ m, mixes and make the product of forms such as capsule, tablet then with ganoderan.Also can be with the ultra-micro powder and the ganoderan of resultant people's Placenta Hominis, and again with vitamin E, vitamin C at least a the mixing after, make corresponding product.Wherein, preferred mode is ultra-micro powder and the ganoderan with people's Placenta Hominis, or add the blending constituent after at least a in vitamin E, the vitamin C again, with in non-oleaginous base PEG400, the polyethylene glycol 6000 one or both, or one or more of soybean oil in the vegetable oil, Semen Maydis oil, sunflower oil, Oleum Bulbus Allii, perilla oil are prepared into the soft capsule product for auxiliary element.
Comparative test result shows that the Halth-care composition of the above-mentioned form of the present invention can keep the bioactive ingredients in people's Placenta Hominis to greatest extent.By pressing the mode of operation of radioimmunoassay medicine box description regulation, measure the interstitialcellstimulating hormone (ICSH) (LH) in the people's placenta component that obtains with conventional process mode and aforesaid way of the present invention respectively, the result of the ripe hormone (FSH) of short folliculus, estradiol (E2), progesterone (P) people Chorionic Gonadotrophin 5 kinds of hormones such as (HCG), as shown in table 1.
The measurement result of hormone-content in the goods after the table 1 different disposal method
| Processing method | LH (Ng/ml) | FSH (mg/ml) | E2 (mg/ml) | P (pg/ml) | HCG (ng/ml) |
| Traditional method | 4 | 2.6 | 39.1 | 6.0 | 1.2 |
| The inventive method | 72.4 | 5.9 | 45.6 | 11.4 | 6.8 |
The result of table 1 shows, adopt the content of each composition in people's Placenta Hominis that the inventive method obtains all to be higher than or apparently higher than the product of traditional method, especially the reservation result with LH is the most remarkable, thereby it not only can strengthen the human body immunity, and delaying sanility, senile plaque or chloasma etc. also all there is the effect that significantly disappears, can obviously be better than the similar medicine and/or the health product that contain placenta component of use at present on the effect, also greatly saved people's Placenta Hominis raw material resources.
The specific embodiment below in conjunction with embodiment is described in further detail foregoing of the present invention again.But this should be interpreted as that the scope of the above-mentioned theme of the present invention only limits to following example.Do not breaking away under the above-mentioned technological thought situation of the present invention, various replacements or change according to ordinary skill knowledge and customary means are made all should comprise within the scope of the invention.
The specific embodiment
Embodiment 1
Placenta Hominis powder: bright people's Placenta Hominis is cleaned bloodstain, remove amniotic membrane and umbilical cord, rub, in stainless steel disc.Place freezer dryer ,-40 ℃～-45 ℃ pre-freezes are after 10 hours, and pressure evacuation when 15Pa distilled 25 hours, was warming up to 0 ℃ gradually, kept 2 hours, adjusted pressure to 20Pa, was warming up to 25 ℃ of dryings gradually 10 hours.The lyophilizing sample is put in the super micron mill, under 5～20 ℃ of temperature, be crushed to the ultra-micro powder that particle diameter is 1 μ m～50 μ m, standby.
Embodiment 2
Take by weighing ganoderan 200g and Placenta Hominis powder (embodiment 1 preparation) 50g, add 750g PEG400 stirring and evenly mixing, make into suspension as content; Gelatin, water, glycerol are made rubber by 1:1:0.3～0.5.Content and rubber are prepared into soft capsule, drying, granulate, and packing promptly.
Embodiment 3
Take by weighing ganoderan 200g and Placenta Hominis powder (embodiment 1 preparation) 50g, add 500g Polyethylene Glycol 650 and 100g polyethylene glycol 6000 stirring and evenly mixing, make into suspension as content; Gelatin, water, glycerol are made rubber by 1:1:0.3～0.5.Content and rubber are prepared into soft capsule, drying, granulate, and packing promptly.
Embodiment 4
Take by weighing ganoderan 150g and Placenta Hominis powder (embodiment 1 preparation) 150g, stirring and evenly mixing adds 400g～700g soybean oil or contains in 0.5%～4% the mellisic soybean oil and makes into suspension as content; Gelatin, water, glycerol are made rubber by 1:1:0.3～0.5.Content and rubber are prepared into soft capsule, drying, granulate, and packing promptly.
Embodiment 5
Take by weighing ganoderan 200g and Placenta Hominis powder (embodiment 1 preparation) 20g, stirring and evenly mixing adds in 400g soybean oil and the 350g Semen Maydis oil (or sunflower oil, Oleum Bulbus Allii, perilla oil) and makes into suspension as content; Gelatin, water, glycerol are made rubber by 1:1:0.3～0.5.Content and rubber are prepared into soft capsule, drying, granulate, and packing promptly.
Embodiment 6
Take by weighing ganoderan 50g and Placenta Hominis powder (embodiment 1 preparation) 250g, vitamin E 3g, vitamin C 10g adds in 400～700g soybean oil or contains in 0.5%～4% the mellisic soybean oil, and stirring and evenly mixing makes into suspension as content; Gelatin, water, glycerol are made rubber by 1:1:0.3～0.5.Content and rubber are prepared into soft capsule, drying, granulate, and packing promptly.
Embodiment 7
Take by weighing ganoderan 200g and Placenta Hominis powder (embodiment 1 preparation) 100g, vitamin E 3g, add in 400～700g soybean oil or contain in 0.5%～4% the mellisic soybean oil, stirring and evenly mixing makes into suspension as content; Gelatin, water, glycerol are made rubber by 1:1:0.3～0.5.Content and rubber are prepared into soft capsule, drying, granulate, and packing promptly.
Embodiment 8
Take by weighing ganoderan 200g and Placenta Hominis powder (embodiment 1 preparation) 100g, vitamin C 10g, add in 400～700g soybean oil or contain in 0.5%～4% the mellisic soybean oil, stirring and evenly mixing makes into suspension as content; Gelatin, water, glycerol are made rubber by 1:1:0.3～0.5.Content and rubber are prepared into soft capsule, drying, granulate, and packing promptly.
Embodiment 9
Take by weighing ganoderan 200g and Placenta Hominis powder (embodiment 1 preparation) 50g, vitamin E 3g, vitamin C 10g, starch 450g, dextrin 90g, sucrose 200g, mixing is made granule.Dry below 60 ℃, add Pulvis Talci 8g, magnesium stearate 2g, mixing, the dress Capsules promptly gets hard capsule.
Embodiment 10
Take by weighing ganoderan 100～500g and Placenta Hominis powder (embodiment 1 preparation) 10～50g, vitamin e1～5g, starch 250～450g, dextrin 45～100g, sucrose 50～100g, mixing is made granule.Dry below 60 ℃, add Pulvis Talci 4～8g, magnesium stearate 0.5～2g, mixing, the dress Capsules promptly gets hard capsule.
Embodiment 11
Take by weighing ganoderan 200g and Placenta Hominis powder (embodiment 1 preparation) 100g and mix, other gets starch 45 grams, dextrin 32 grams, sucrose 10g, pulverize separately cross 100 mesh sieves, the above-mentioned raw materials mixing, add water and make soft material, cross 30 orders and granulate, dry below 60 ℃, 30 order granulate add Pulvis Talci 10g, magnesium stearate 3g, mixing, be pressed into 1000, coating promptly gets tablet.
Below prove effect of the present invention by clinical trial.
With the soft capsule that makes in the example 2, and replace people's Placenta Hominis powder, the hard capsule comparative test that makes under the identical situation of component with the Placenta caprae seu ovis powder.
Carry out the result of use contrast test with present composition sample and Comparative Examples:
Present composition sample is formed (0.25g/ grain): contain people's Placenta Hominis powder 12.5mg (with proteinometer), ganoderan 50mg.
Comparative example is formed (0.25g/ grain): contain Placenta caprae seu ovis powder 12.5mg, ganoderan 50mg.
Test and Selection object: every group of each 10 people, readme and external inspection symptom basically identical in person.
Instructions of taking: each oral 2, every day 3 times, statistical observation after three months, the result is as shown in table 2.
Table 2 comparative test result
| Symptom | Green around the gills | General weakness | Do not have enough sleep | Often catch a cold |
| Sample of the present invention | 10 people glowing with health | Energetic 10 people | Good 9 people sleep | Obviously reduce by 8 people |
| Comparative example | 6 people glowing with health | Energetic 5 people | Good 4 people sleep | Obviously reduce by 4 people |
The comparative test result of table 2 shows that compositions of the present invention can obviously strengthen the human body immunity, and obviously is better than the Comparative Examples goods of Placenta caprae seu ovis composition.
Claims (10)
1. the Halth-care composition that contains placenta component, it is characterized in that with ganoderan and people's Placenta Hominis powder be basic effective constituents, form jointly with acceptable auxiliary element in the pharmacy, the weight ratio of ganoderan and people's Placenta Hominis powder of representing with albumen quality is 1/ (0.1～5) in the effective ingredient.
2. the Halth-care composition that contains placenta component as claimed in claim 1 is characterized in that ganoderan in the said effective ingredient and the weight ratio of people's Placenta Hominis powder of representing with albumen quality is 1/ (0.1～1).
3. the Halth-care composition that contains placenta component as claimed in claim 1 is characterized in that said people's Placenta Hominis powder is that particle diameter is the ultra-micro powder of 1 μ m～50 μ m.
4. the Halth-care composition that contains placenta component as claimed in claim 3 is characterized in that said people's Placenta Hominis powder is the people's Placenta Hominis dried powder that obtains in the freezing and sublimation mode under-40 ℃～-45 ℃ and 15Pa～25Pa condition.
5. the Halth-care composition that contains placenta component as claimed in claim 1 is characterized in that in the said effective ingredient also having at least a in vitamin E, the vitamin C.
6. as the described Halth-care composition that contains placenta component of one of claim 1～5, it is characterized in that the soft capsule preparation form that is prepared into by said effective ingredient and auxiliary element, auxiliary element wherein is Polyethylene Glycol or vegetable oil.
7. the Halth-care composition that contains placenta component as claimed in claim 6, it is characterized in that said Polyethylene Glycol is at least a in PEG400 and the polyethylene glycol 6000, said vegetable oil is at least a in soybean oil, Semen Maydis oil, sunflower oil, Oleum Bulbus Allii and the perilla oil.
8. prepare the described method that contains the Halth-care composition of placenta component of claim 1, it is characterized in that people's Placenta Hominis after fully freezing under-40 ℃～-45 ℃ conditions, after 15Pa～25Pa lyophilization, being crushed to particle diameter is the ultra-micro powder of 1 μ m～50 μ m, is mixed and made into the product of capsule or tablet form then with ganoderan.
9. preparation method as claimed in claim 8 is characterized in that ultra-micro powder and ganoderan with resultant people's Placenta Hominis, and after at least a mixing in the vitamin E, vitamin C, makes corresponding product.
10. preparation method as claimed in claim 8 or 9, it is characterized in that ultra-micro powder and ganoderan with people's Placenta Hominis, or also add the blending constituent after at least a in vitamin E, the vitamin C, with be selected from least a in non-oleaginous base PEG400, the polyethylene glycol 6000, or be selected from least a in soybean oil, Semen Maydis oil, sunflower oil, Oleum Bulbus Allii, the perilla oil and be prepared into soft capsule for auxiliary element.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008101477737A CN101433556A (en) | 2008-12-05 | 2008-12-05 | Health product composition containing placenta component and preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008101477737A CN101433556A (en) | 2008-12-05 | 2008-12-05 | Health product composition containing placenta component and preparation method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101433556A true CN101433556A (en) | 2009-05-20 |
Family
ID=40708298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2008101477737A Pending CN101433556A (en) | 2008-12-05 | 2008-12-05 | Health product composition containing placenta component and preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101433556A (en) |
Cited By (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130344162A1 (en) * | 2011-02-14 | 2013-12-26 | Brenda S. Morse | Micronized placental tissue compositions and methods of making and using the same |
| CN103639087A (en) * | 2013-11-25 | 2014-03-19 | 际华三五一五皮革皮鞋有限公司 | Pneumatic manipulator type linear spraying device |
| US8904664B2 (en) | 2012-08-15 | 2014-12-09 | Mimedx Group, Inc. | Dehydration device and methods for drying biological materials |
| CN104873544A (en) * | 2014-10-14 | 2015-09-02 | 磐安县道地磐药中药研究所 | Pure sheep placenta powder and its preparation method and use |
| US9180145B2 (en) | 2012-10-12 | 2015-11-10 | Mimedx Group, Inc. | Compositions and methods for recruiting and localizing stem cells |
| CN105030831A (en) * | 2015-09-19 | 2015-11-11 | 山东中泰药业有限公司 | Placental drug and preparation method thereof |
| CN105724892A (en) * | 2014-12-11 | 2016-07-06 | 国玺干细胞应用技术股份有限公司 | Food supplement for resisting aging and rejuvenating |
| US9446142B2 (en) | 2013-05-28 | 2016-09-20 | Mimedx Group, Inc. | Polymer chelator conjugates |
| US9655948B1 (en) * | 2013-01-17 | 2017-05-23 | Mimedx Group, Inc. | Non-surgical, localized delivery of compositions for placental growth factors |
| US9662355B2 (en) | 2013-01-18 | 2017-05-30 | Mimedx Group, Inc. | Methods for treating cardiac conditions |
| CN107296271A (en) * | 2017-07-11 | 2017-10-27 | 江苏希瑞干细胞技术有限公司 | A kind of placenta capsule and preparation method thereof |
| US9827293B2 (en) | 2013-01-17 | 2017-11-28 | Mimedx Group, Inc. | Non-surgical, localized delivery of compositions for placental growth factors |
| US9943551B2 (en) | 2012-08-15 | 2018-04-17 | Mimedx Group, Inc. | Tissue grafts composed of micronized placental tissue and methods of making and using the same |
| US10029030B2 (en) | 2013-03-15 | 2018-07-24 | Mimedx Group, Inc. | Molded placental tissue compositions and methods of making and using the same |
| US10052351B2 (en) | 2014-01-17 | 2018-08-21 | Mimedx Group, Inc. | Method for inducing angiogenesis |
| US10159744B2 (en) | 2012-11-19 | 2018-12-25 | Mimedx Group, Inc. | Cross-linked collagen comprising metallic anticancer agents |
| US10206977B1 (en) | 2013-01-18 | 2019-02-19 | Mimedx Group, Inc. | Isolated placental stem cell recruiting factors |
| US10441664B2 (en) | 2012-11-19 | 2019-10-15 | Mimedx Group, Inc. | Cross-linked collagen with at least one bound antimicrobial agent for in vivo release of the agent |
| US10517931B2 (en) | 2013-01-17 | 2019-12-31 | Mimedx Group, Inc. | Non-surgical, localized delivery of compositions for placental growth factors |
| US10617785B2 (en) | 2014-08-28 | 2020-04-14 | Mimedx Group, Inc. | Collagen reinforced tissue grafts |
| US10857266B2 (en) | 2012-08-15 | 2020-12-08 | Mimedx Group, Inc. | Reinforced placental tissue grafts and methods of making and using the same |
| CN114712323A (en) * | 2022-05-18 | 2022-07-08 | 贵州奇源生物制品有限公司 | Human placenta tablet and preparation method thereof |
| US12290613B2 (en) | 2011-10-06 | 2025-05-06 | Mimedx Group, Inc. | Micronized compositions composed of bone grafts and methods of making and using the same |
-
2008
- 2008-12-05 CN CNA2008101477737A patent/CN101433556A/en active Pending
Cited By (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10105398B2 (en) | 2011-02-14 | 2018-10-23 | Mimedx Group, Inc. | Micronized placental tissue compositions and methods of making and using the same |
| US11103536B2 (en) | 2011-02-14 | 2021-08-31 | Mimedx Group, Inc. | Micronized placental tissue compositions and methods of making and using the same |
| US20130344162A1 (en) * | 2011-02-14 | 2013-12-26 | Brenda S. Morse | Micronized placental tissue compositions and methods of making and using the same |
| US11931384B2 (en) | 2011-02-14 | 2024-03-19 | Mimedx Group, Inc. | Micronized placental tissue compositions and methods of making and using the same |
| US10105397B2 (en) * | 2011-02-14 | 2018-10-23 | Mimedx Group, Inc. | Micronized placental tissue compositions and methods of making and using the same |
| US11235007B2 (en) | 2011-02-14 | 2022-02-01 | Mimedx Group, Inc. | Micronized placental tissue compositions and methods of making and using the same |
| US10376546B2 (en) | 2011-02-14 | 2019-08-13 | Mimedx Group, Inc. | Micronized placental tissue compositions and methods of making and using the same |
| US11219647B2 (en) | 2011-02-14 | 2022-01-11 | Mimedx Group, Inc. | Micronized placental tissue compositions and methods of making and using the same |
| US12290613B2 (en) | 2011-10-06 | 2025-05-06 | Mimedx Group, Inc. | Micronized compositions composed of bone grafts and methods of making and using the same |
| US11607430B2 (en) | 2012-08-15 | 2023-03-21 | Mimedx Group, Inc. | Tissue grafts composed of micronized placental tissue and methods of making and using the same |
| US12208180B2 (en) | 2012-08-15 | 2025-01-28 | Mimedx Group, Inc. | Reinforced placental tissue grafts and methods of making and using the same |
| US10857266B2 (en) | 2012-08-15 | 2020-12-08 | Mimedx Group, Inc. | Reinforced placental tissue grafts and methods of making and using the same |
| US9943551B2 (en) | 2012-08-15 | 2018-04-17 | Mimedx Group, Inc. | Tissue grafts composed of micronized placental tissue and methods of making and using the same |
| US8904664B2 (en) | 2012-08-15 | 2014-12-09 | Mimedx Group, Inc. | Dehydration device and methods for drying biological materials |
| US9180145B2 (en) | 2012-10-12 | 2015-11-10 | Mimedx Group, Inc. | Compositions and methods for recruiting and localizing stem cells |
| US10159744B2 (en) | 2012-11-19 | 2018-12-25 | Mimedx Group, Inc. | Cross-linked collagen comprising metallic anticancer agents |
| US10441664B2 (en) | 2012-11-19 | 2019-10-15 | Mimedx Group, Inc. | Cross-linked collagen with at least one bound antimicrobial agent for in vivo release of the agent |
| US11690896B2 (en) | 2013-01-17 | 2023-07-04 | Mimedx Group, Inc. | Non-surgical, localized delivery of compositions for placental growth factors |
| US9827293B2 (en) | 2013-01-17 | 2017-11-28 | Mimedx Group, Inc. | Non-surgical, localized delivery of compositions for placental growth factors |
| US9655948B1 (en) * | 2013-01-17 | 2017-05-23 | Mimedx Group, Inc. | Non-surgical, localized delivery of compositions for placental growth factors |
| US10517931B2 (en) | 2013-01-17 | 2019-12-31 | Mimedx Group, Inc. | Non-surgical, localized delivery of compositions for placental growth factors |
| US9662355B2 (en) | 2013-01-18 | 2017-05-30 | Mimedx Group, Inc. | Methods for treating cardiac conditions |
| US10111910B2 (en) | 2013-01-18 | 2018-10-30 | Mimedx Group, Inc. | Methods for treating cardiac conditions |
| US11648281B2 (en) | 2013-01-18 | 2023-05-16 | Mimedx Group, Inc. | Methods for treating cardiac conditions |
| US10206977B1 (en) | 2013-01-18 | 2019-02-19 | Mimedx Group, Inc. | Isolated placental stem cell recruiting factors |
| US11000553B2 (en) | 2013-01-18 | 2021-05-11 | Mimedx Group, Inc. | Placental tissue composition for for treating cardiac tissue damage |
| US11497791B1 (en) | 2013-01-18 | 2022-11-15 | Mimedx Group, Inc. | Isolated placental stem cell recruiting factors |
| US11389565B2 (en) | 2013-03-15 | 2022-07-19 | Mimedx Group, Inc. | Molded placental tissue compositions and methods of making and using the same |
| US10029030B2 (en) | 2013-03-15 | 2018-07-24 | Mimedx Group, Inc. | Molded placental tissue compositions and methods of making and using the same |
| US9446142B2 (en) | 2013-05-28 | 2016-09-20 | Mimedx Group, Inc. | Polymer chelator conjugates |
| CN103639087A (en) * | 2013-11-25 | 2014-03-19 | 际华三五一五皮革皮鞋有限公司 | Pneumatic manipulator type linear spraying device |
| US10842824B2 (en) | 2014-01-17 | 2020-11-24 | Mimedx Group, Inc. | Method for inducing angiogenesis |
| US10052351B2 (en) | 2014-01-17 | 2018-08-21 | Mimedx Group, Inc. | Method for inducing angiogenesis |
| US12433971B2 (en) | 2014-08-28 | 2025-10-07 | Mimedx Group, Inc. | Collagen reinforced tissue grafts |
| US10617785B2 (en) | 2014-08-28 | 2020-04-14 | Mimedx Group, Inc. | Collagen reinforced tissue grafts |
| CN104873544A (en) * | 2014-10-14 | 2015-09-02 | 磐安县道地磐药中药研究所 | Pure sheep placenta powder and its preparation method and use |
| CN105724892B (en) * | 2014-12-11 | 2019-06-18 | 国玺干细胞应用技术股份有限公司 | Food supplement for promoting stem cell proliferation and increasing telomerase activity |
| CN105724892A (en) * | 2014-12-11 | 2016-07-06 | 国玺干细胞应用技术股份有限公司 | Food supplement for resisting aging and rejuvenating |
| CN105030831A (en) * | 2015-09-19 | 2015-11-11 | 山东中泰药业有限公司 | Placental drug and preparation method thereof |
| CN107296271A (en) * | 2017-07-11 | 2017-10-27 | 江苏希瑞干细胞技术有限公司 | A kind of placenta capsule and preparation method thereof |
| CN114712323A (en) * | 2022-05-18 | 2022-07-08 | 贵州奇源生物制品有限公司 | Human placenta tablet and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101433556A (en) | Health product composition containing placenta component and preparation method | |
| US20210352948A1 (en) | Composition for treating diabetes based on traditional Chinese medicine nutritional therapy and application thereof | |
| CN103355679B (en) | Making method of chewable tablet with effect of enriching blood | |
| CN103815282B (en) | Preparation method for sea cucumber wheaten food | |
| WO2019080848A1 (en) | Fine bamboo powder and preparation method therefor and use thereof | |
| CN105770799A (en) | Granular preparation with brain memory improving function | |
| CN110179125A (en) | A kind of composition and preparation method thereof promoting Recovery | |
| CN105596646A (en) | Medicine, health-care product or food composition for controlling blood glucose and treating abnormal blood lipid metabolism | |
| Kumar et al. | Pasta: Raw materials, processing and quality improvement | |
| CN102178217B (en) | Konjac-flour-containing mixture and preparation method thereof | |
| CN102488189B (en) | Capsule with health-care function of assisting blood lipid reduction and preparation method thereof | |
| CN104432055B (en) | Anti-caking grape seed superfine powder composition without additives and preparation method thereof | |
| CN103961396A (en) | Healthy soft capsule and preparation process thereof | |
| CN101642251B (en) | Nutritive rice suitable for middle-aged and elderly people and processing method thereof | |
| CN103039626B (en) | Black bean powder for tonifying spleen and kidney and preparation method thereof | |
| CN106107395A (en) | A kind of Fructus Citri Limoniae solid ginger beverage and preparation method thereof | |
| CN113288941A (en) | Composition containing raspberry exosome for maintaining ovary and preparation method thereof | |
| CN106578945A (en) | Nutritive compound rice eaten by lying-in women and preparation method thereof | |
| CN116268431B (en) | Composition for improving or promoting whey protein absorption and application thereof | |
| CN106260381A (en) | A kind of resveratrol pressed candy of applicable diabetes patient and preparation method thereof | |
| CN101011073A (en) | Ginko-wheat composite powder and its producing technology | |
| CN101574145A (en) | Nutritional reinforced supplement | |
| CN110269221A (en) | Plant nutrient promotor composition, preparation method and anti-oxidation function food | |
| CN104137999B (en) | The healthcare products that the dietetic therapeutic composition of a kind of fat-reducing of reducing weight and auxiliary material obtain and its preparation method | |
| CN107752000A (en) | A kind of colla corii asini cake preparation method for postpartum recuperating |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20090520 |